494 related articles for article (PubMed ID: 25872159)
1. Advances and challenges in PBPK modeling--Analysis of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base.
Berlin M; Ruff A; Kesisoglou F; Xu W; Wang MH; Dressman JB
Eur J Pharm Biopharm; 2015 Jun; 93():267-80. PubMed ID: 25872159
[TBL] [Abstract][Full Text] [Related]
2. Prediction of oral absorption of cinnarizine--a highly supersaturating poorly soluble weak base with borderline permeability.
Berlin M; Przyklenk KH; Richtberg A; Baumann W; Dressman JB
Eur J Pharm Biopharm; 2014 Nov; 88(3):795-806. PubMed ID: 25195981
[TBL] [Abstract][Full Text] [Related]
3. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.
Shono Y; Jantratid E; Dressman JB
Eur J Pharm Biopharm; 2011 Oct; 79(2):349-56. PubMed ID: 21527341
[TBL] [Abstract][Full Text] [Related]
4. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
[TBL] [Abstract][Full Text] [Related]
5. Exploring the impact of real-life dosing conditions on intraluminal and systemic concentrations of atazanavir in parallel with gastric motility recording in healthy subjects.
Hens B; Masuy I; Deloose E; Mols R; Tack J; Augustijns P
Eur J Pharm Biopharm; 2020 May; 150():66-76. PubMed ID: 32113916
[TBL] [Abstract][Full Text] [Related]
6. Atazanavir-loaded Eudragit RL 100 nanoparticles to improve oral bioavailability: optimization and in vitro/in vivo appraisal.
Singh G; Pai RS
Drug Deliv; 2016; 23(2):532-9. PubMed ID: 24963752
[TBL] [Abstract][Full Text] [Related]
7. Predicting the oral pharmacokinetic profiles of multiple-unit (pellet) dosage forms using a modeling and simulation approach coupled with biorelevant dissolution testing: case example diclofenac sodium.
Kambayashi A; Blume H; Dressman JB
Eur J Pharm Biopharm; 2014 Jul; 87(2):236-43. PubMed ID: 24462791
[TBL] [Abstract][Full Text] [Related]
8. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
Kambayashi A; Blume H; Dressman J
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
[TBL] [Abstract][Full Text] [Related]
9. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
[TBL] [Abstract][Full Text] [Related]
10. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
12. Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state.
Brouwers J; Tack J; Augustijns P
Pharm Res; 2007 Oct; 24(10):1862-9. PubMed ID: 17443397
[TBL] [Abstract][Full Text] [Related]
13. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
[TBL] [Abstract][Full Text] [Related]
14. Utilizing physiologically based pharmacokinetic modeling to inform formulation and clinical development for a compound with pH-dependent solubility.
Chung J; Alvarez-Nunez F; Chow V; Daurio D; Davis J; Dodds M; Emery M; Litwiler K; Paccaly A; Peng J; Rock B; Wienkers L; Yang C; Yu Z; Wahlstrom J
J Pharm Sci; 2015 Apr; 104(4):1522-32. PubMed ID: 25641187
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers.
Rubbens J; Brouwers J; Tack J; Augustijns P
Eur J Pharm Biopharm; 2016 Dec; 109():122-129. PubMed ID: 27693678
[TBL] [Abstract][Full Text] [Related]
16. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
17. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
18. Prediction of pH dependent absorption using in vitro, in silico, and in vivo rat models: Early liability assessment during lead optimization.
Saxena A; Shah D; Padmanabhan S; Gautam SS; Chowan GS; Mandlekar S; Desikan S
Eur J Pharm Sci; 2015 Aug; 76():173-80. PubMed ID: 25960252
[TBL] [Abstract][Full Text] [Related]
19. Use of biorelevant dissolution and PBPK modeling to predict oral drug absorption.
Kaur N; Narang A; Bansal AK
Eur J Pharm Biopharm; 2018 Aug; 129():222-246. PubMed ID: 29879527
[TBL] [Abstract][Full Text] [Related]
20. A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling.
Gao Y; Carr RA; Spence JK; Wang WW; Turner TM; Lipari JM; Miller JM
Mol Pharm; 2010 Oct; 7(5):1516-26. PubMed ID: 20715778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
